EFFECT OF SILDENAFIL ON UTERINE BLOOD FLOW IN NON-PREGNANT WOMEN

西地那非对非孕妇子宫血流的影响

基本信息

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. During pregnancy, blood flow to the uterus (womb) and placenta must increase a lot to support a normal pregnancy. This is accomplished by a combination of blood vessel growth, the creation of new blood vessels, and an increased ability of existing blood vessels to open up. Several diseases of pregnancy such as preeclampsia (toxemia) and fetal growth restriction are associated with insufficient uterine blood flow, and there are no current therapies that can selectively improved uterine blood flow. In particular, there are no drugs that will increase blood flow to the uterus only; as most drugs that increase blood flow are relatively nonspecific and result in widespread increase in blood flow to all organs that ultimately results in a vascular redistribution that reduces blood flow to the uterus. Sildenafil (Viagra) has been used to increase blood flow to the penis in men (hence its use in improving erectile dysfunction). Its relative specificity derives from its ability to inhibit an enzyme, phosphodiesterase 5 (PDE5), which is not present everywhere in the body, but has been localized in the blood vessels of the reproductive organs, and in the vessels of the lung. The latter effect has been recognized as a potential therapy for pulmonary hypertension. Several recent studies have shown that sildenafil is also able to induce dilation of arteries isolated from the human uterus (see references, below), although it's hemodynamic effects on uterine blood flow have yet to be defined. The purpose of this study is to definitively answer this question by measuring uterine blood flow in nonpregnant women with transvaginal ultrasound. If a significant and specific effect is observed, we will consider extending these studies to women who are pregnant and, eventually, to those that have clinically significant reductions in uterine blood flow as are sometimes evident in preeclamptics. The pilot protocol will involve recruiting 30 nonpregnant women, 2/3 of whom will receive Sildenafil (split evenly among 2 different standard clinical doses), and 1/3 of whom will receive no medication is a manner that is blinded to the clinical investigator.
该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金, 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说,它不一定是研究者的机构。 怀孕期间,流向子宫和胎盘的血流量必须大量增加才能支持正常怀孕。 这是通过血管生长、新血管的产生以及现有血管开放能力的增强相结合来实现的。 一些妊娠疾病,如先兆子痫(毒血症)和胎儿生长受限与子宫血流不足有关,目前没有可以选择性改善子宫血流的治疗方法。 特别是,没有任何药物可以只增加子宫的血流量。因为大多数增加血流量的药物相对非特异性,会导致流向所有器官的血流量广泛增加,最终导致血管重新分布,从而减少流向子宫的血流量。 西地那非(伟哥)已被用于增加男性阴茎的血流量(因此可用于改善勃起功能障碍)。 其相对特异性源自其抑制磷酸二酯酶 5 (PDE5) 的能力,这种酶并不存在于体内各处,但只存在于生殖器官的血管和肺血管中。 后一种作用已被认为是肺动脉高压的潜在疗法。 最近的几项研究表明,西地那非还能够引起从人类子宫分离出来的动脉扩张(见下文参考文献),尽管它对子宫血流的血流动力学影响尚未确定。 本研究的目的是通过经阴道超声测量非孕妇的子宫血流量来明确回答这个问题。 如果观察到显着且具体的效果,我们将考虑将这些研究扩展到怀孕妇女,并最终扩展到那些临床上子宫血流量显着减少的妇女(有时在先兆子痫中很明显)。 试点方案将招募 30 名非孕妇,其中 2/3 将接受西地那非(平均分配为 2 种不同的标准临床剂量),其中 1/3 将不接受任何药物治疗,这种方式对临床研究人员是不知情的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IRA MARK BERNSTEIN其他文献

IRA MARK BERNSTEIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IRA MARK BERNSTEIN', 18)}}的其他基金

The interaction of basal risk, pharmacologic ovulation induction, pregnancy and delivery on hemostatic balance
基础风险、药物促排卵、妊娠和分娩对止血平衡的相互作用
  • 批准号:
    10026344
  • 财政年份:
    2018
  • 资助金额:
    $ 0.38万
  • 项目类别:
The interaction of basal risk, pharmacologic ovulation induction, pregnancy and delivery on hemostatic balance
基础风险、药物促排卵、妊娠和分娩对止血平衡的相互作用
  • 批准号:
    10390293
  • 财政年份:
    2018
  • 资助金额:
    $ 0.38万
  • 项目类别:
PREDISPOSITION TO DEVELOP PREECLAMPSIA
发生先兆子痫的倾向
  • 批准号:
    8166964
  • 财政年份:
    2010
  • 资助金额:
    $ 0.38万
  • 项目类别:
WRHR - A Mentoring Program in Women's Reproductive Health Research at the Univers
WRHR - 大学妇女生殖健康研究的指导计划
  • 批准号:
    8136293
  • 财政年份:
    2009
  • 资助金额:
    $ 0.38万
  • 项目类别:
PREDISPOSITION TO DEVELOP PREECLAMPSIA
发生先兆子痫的倾向
  • 批准号:
    7952098
  • 财政年份:
    2009
  • 资助金额:
    $ 0.38万
  • 项目类别:
EFFECT OF SILDENAFIL ON UTERINE BLOOD FLOW IN NON-PREGNANT WOMEN
西地那非对非孕妇子宫血流的影响
  • 批准号:
    7952108
  • 财政年份:
    2009
  • 资助金额:
    $ 0.38万
  • 项目类别:
WRHR - A Mentoring Program in Women's Reproductive Health Research at the Univers
WRHR - 大学妇女生殖健康研究的指导计划
  • 批准号:
    8323541
  • 财政年份:
    2009
  • 资助金额:
    $ 0.38万
  • 项目类别:
WRHR - A Mentoring Program in Women's Reproductive Health Research at the Univers
WRHR - 大学妇女生殖健康研究的指导计划
  • 批准号:
    8525413
  • 财政年份:
    2009
  • 资助金额:
    $ 0.38万
  • 项目类别:
PREDISPOSITION TO DEVELOP PREECLAMPSIA
发生先兆子痫的倾向
  • 批准号:
    7605793
  • 财政年份:
    2007
  • 资助金额:
    $ 0.38万
  • 项目类别:
PREDISPOSITION TO DEVELOP PREECLAMPSIA
发生先兆子痫的倾向
  • 批准号:
    7378576
  • 财政年份:
    2006
  • 资助金额:
    $ 0.38万
  • 项目类别:

相似海外基金

De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 0.38万
  • 项目类别:
    Operating Grants
The effectiveness of oral cannabis extracts for osteoarthritic pain: an internal pilot, placebo controlled, blinded randomized trial
口服大麻提取物对骨关节炎疼痛的有效性:一项内部试点、安慰剂对照、盲法随机试验
  • 批准号:
    479511
  • 财政年份:
    2023
  • 资助金额:
    $ 0.38万
  • 项目类别:
    Operating Grants
IMPACT, a supervised rehabilitation program for spastic ataxias: A rater-blinded, randomized controlled trial
IMPACT,痉挛性共济失调的监督康复计划:一项评估者盲法、随机对照试验
  • 批准号:
    468464
  • 财政年份:
    2022
  • 资助金额:
    $ 0.38万
  • 项目类别:
    Operating Grants
Lineup construction methods: Should lineup constructors be blinded to the suspect?
阵容构建方法:阵容构建者是否应该对嫌疑人视而不见?
  • 批准号:
    2754233
  • 财政年份:
    2022
  • 资助金额:
    $ 0.38万
  • 项目类别:
    Studentship
ZZ-3K3A-301: A multicenter, randomized, placebo-controlled, double-blinded, Phase 3 study to evaluate the efficacy and safety of 3K3A-APC (RHAPSODY-2)
ZZ-3K3A-301:一项多中心、随机、安慰剂对照、双盲、3 期研究,旨在评估 3K3A-APC (RHAPSODY-2) 的有效性和安全性
  • 批准号:
    10305528
  • 财政年份:
    2022
  • 资助金额:
    $ 0.38万
  • 项目类别:
Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons with Post-COVID-19 Condition
评估沃替西汀对 COVID-19 后患者认知缺陷的随机、双盲、安慰剂对照研究
  • 批准号:
    467059
  • 财政年份:
    2021
  • 资助金额:
    $ 0.38万
  • 项目类别:
    Studentship Programs
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias
不同 α-突触核蛋白接种测定作为路易体痴呆皮肤生物标志物的盲法比较
  • 批准号:
    10458459
  • 财政年份:
    2021
  • 资助金额:
    $ 0.38万
  • 项目类别:
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias
不同 α-突触核蛋白接种测定作为路易体痴呆皮肤生物标志物的盲法比较
  • 批准号:
    10674759
  • 财政年份:
    2021
  • 资助金额:
    $ 0.38万
  • 项目类别:
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias
不同 α-突触核蛋白接种测定作为路易体痴呆皮肤生物标志物的盲法比较
  • 批准号:
    10064563
  • 财政年份:
    2021
  • 资助金额:
    $ 0.38万
  • 项目类别:
Discontinuation of levothyroxine therapy for patients with subclinical hypothyroidism: a pilot randomized, double-blinded, placebo-controlled study
亚临床甲状腺功能减退症患者停止左旋甲状腺素治疗:一项随机、双盲、安慰剂对照试验研究
  • 批准号:
    10337077
  • 财政年份:
    2021
  • 资助金额:
    $ 0.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了